Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy
Open Access
- 25 September 2019
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 121 (9) , 758-767
Abstract
Background: Protoporphyrin IX (PpIX) gets accumulated preferentially in 5-aminolevulinic acid (5-ALA)-treated cancer cells. Photodynamic therapy (PDT) utilises the accumulated PpIX to trigger cell death by light-induced generation of reactive oxygen species (ROS). We previously demonstrated that oncogenic Ras/MEK decreases PpIX accumulation in cancer cells. Here, we investigated whether combined therapy with a MEK inhibitor would improve 5-ALA-PDT efficacy.Methods: Cancer cells and mice models of cancer were treated with 5-ALA-PDT, MEK inhibitor or both MEK inhibitor and 5-ALA-PDT, and treatment efficacies were evaluated.Results: Ras/MEK negatively regulates the cellular sensitivity to 5-ALA-PDT as cancer cells pre-treated with a MEK inhibitor were killed more efficiently by 5-ALA-PDT. MEK inhibition promoted 5-ALA-PDT-induced ROS generation and programmed cell death. Furthermore, the combination of 5-ALA-PDT and a systemic MEK inhibitor significantly suppressed tumour growth compared with either monotherapy in mouse models of cancer. Remarkably, 44% of mice bearing human colon tumours showed a complete response with the combined treatment.Conclusion: We demonstrate a novel strategy to promote 5-ALA-PDT efficacy by targeting a cell signalling pathway regulating its sensitivity. This preclinical study provides a strong basis for utilising MEK inhibitors, which are approved for treating cancers, to enhance 5-ALA-PDT efficacy in the clinic.Keywords
Funding Information
- Beatrice Hunter Cancer Research Institute
- Terry Fox Foundation
- Canadian Cancer Society Research Institute
- Memorial University of Newfoundland Medical Research Fund
This publication has 55 references indexed in Scilit:
- Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cellsPhotodiagnosis and Photodynamic Therapy, 2013
- Mitoferrin-2-dependent Mitochondrial Iron Uptake Sensitizes Human Head and Neck Squamous Carcinoma Cells to Photodynamic TherapyJournal of Biological Chemistry, 2013
- Photodynamic therapy of cancer: An updateCA: A Cancer Journal for Clinicians, 2011
- Photodynamic therapy outcome for oral dysplasiaLasers in Surgery and Medicine, 2011
- The relationship between protoporphyrin IX photobleaching during real‐time dermatological methyl‐aminolevulinate photodynamic therapy (MAL‐PDT) and subsequent clinical outcomeLasers in Surgery and Medicine, 2010
- Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein ResponseCancer Research, 2009
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Mechanisms in photodynamic therapy: part one—photosensitizers, photochemistry and cellular localizationPhotodiagnosis and Photodynamic Therapy, 2004
- Characterization of Endogenous Protoporphyrin IX Induced by δ-Aminolevulinic Acid in Resting and Activated Peripheral Blood Lymphocytes by Four-Color Flow CytometryPhotochemistry and Photobiology, 1998
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI: Journal of the National Cancer Institute, 1994